度洛西汀联合喹硫平治疗躯体形式障碍对照研究

目的 探讨度洛西汀联合喹硫平治疗躯体形式障碍的临床疗效和安全性.方法 将60例躯体形式障碍患者按就诊顺序分为两组,均口服度洛西汀治疗,研究组联合喹硫平治疗,观察8周.采用症状自评量表躯体化因子及汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应.结果 研究组治疗各时段症状自评量表躯体化因子分均显著低于对照组（P＜0.05）,治疗8周末痊愈率、有效率均显著高于对照组（P＜0.05）.两组不良反应均较轻微,经对症处理后逐渐缓解或消失.结论 度洛西汀联合喹硫平治疗躯体形式障碍患者较单用度洛西汀起效快,疗效更显著,且安全性高,依从性好.

A control study of duloxetine plus quetiapine in the treatment of somatoform disorders

Objective To explore the efficacy and safety of duloxetine plus quetiapine in the treatment of somatoform disorders （SD）. Methods Sixty SD patients were assigned to two groups according to diagnostic order, both groups took orally duloxetine, and research groups was plus quetiapine for 8 weeks. Efficacies were assessed with the somatization of Symptom Checklist-90 and Hamilton Depression Scale （HAMD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results The somatization scores at all time-points were significantly lower （P〈0.05） and cure and effective rate higher at the end of the 8^th week （P〈0.05） in research than control group. Adverse reactions of both groups were mild and gradually relieved or disappeared after symptomatic treatment. Conclusion Duloxetine plus quetiapine takes effect more rapidly and has an evident effect, higher safety and better compliance compared with single duloxetine in the treatment of somatoform disorders.